Figure 1. Odds ratio of being discharged on clopidogrel following STEMI. Numbers represented next to the group are odds ratio (confidence interval). STEMI: ST-elevation myocardial infarction; CI: confidence interval.
| Cardiology Research, ISSN 1923-2829 print, 1923-2837 online, Open Access |
| Article copyright, the authors; Journal compilation copyright, Cardiol Res and Elmer Press Inc |
| Journal website https://www.cardiologyres.org |
Original Article
Volume 15, Number 3, June 2024, pages 129-133
Disparity in the Under-Utilization of Novel P2Y12 Inhibitors in ST-Elevation Myocardial Infarction Following Percutaneous Coronary Intervention
Figure
Tables
| Baseline | Clopidogrel (n = 188) | Ticagrelor (n = 125) | Prasugrel (n = 53) |
|---|---|---|---|
| Quantitative values have measure of central tendency and dispersion in parenthesis, and qualitative values have number and percentage of the total in parenthesis. STEMI: ST-elevation myocardial infarction; AA: African Americans; BMI: body mass index; TIA: transient ischemic attack; ESRD: end-stage renal disease; HD: hemodialysis; PVD: peripheral vascular disease. | |||
| Age (mean) | 65 (± 12.5) | 60 (± 12.0) | 54 (± 9.9) |
| Age ≥ 75 | 49 (26.1%) | 13 (10.4%) | 0 (0%) |
| Female sex | 65 (34.6%) | 34 (27.2%) | 11 (20.8%) |
| Male sex | 123 (65.4%) | 91 (72.8%) | 42 (79.2%) |
| Race | |||
| White | 118 (62.8%) | 88 (70.4%) | 37 (69.8%) |
| AA | 54 (28.7%) | 28 (22.4%) | 12 (22.6%) |
| Asian | 6 (3.2%) | 4 (3.2%) | 2 (3.8%) |
| Hispanic | 5 (2.7%) | 2 (1.6%) | 0 (0%) |
| Health insurance | |||
| Medicare | 72 (38.3%) | 35 (28.0%) | 4 (7.5%) |
| Medicaid | 19 (10.1%) | 9 (7.2%) | 5 (9.4%) |
| Private | 142 (75.5%) | 99 (79.2%) | 47 (88.7%) |
| No insurance | 5 (2.7%) | 1 (0.8%) | 0 (0%) |
| BMI | 30 (± 6.3) | 28 (± 5.4) | 29 (± 5.2) |
| Weight < 60 kg | 11 (5.9%) | 6 (4.8%) | 1 (1.9%) |
| Current/recent smoker | 59 (31.4%) | 34 (27.2%) | 18 (34.0%) |
| Hypertension | 133 (70.7%) | 89 (71.2%) | 27 (50.9%) |
| Diabetes | 53 (28.2%) | 39 (31.2%) | 13 (24.5%) |
| ESRD on HD | 1 (0.5%) | 1 (0.8%) | 1 (1.9%) |
| Dyslipidemia | 108 (57.4%) | 74 (59.2%) | 23 (43.4%) |
| Stroke/TIA | 19 (10.1%) | 12 (9.6%) | 0 (0%) |
| PVD | 7 (3.7%) | 7 (5.6%) | 0 (0%) |
| Chronic lung disease | 16 (8.5%) | 11 (8.8%) | 3 (5.7%) |
| Apixaban | 21 (11.2%) | 3 (2.4%) | 2 (3.8%) |
| Rivaroxaban | 5 (2.7%) | 1 (0.8%) | 0 (0%) |
| Dabigatran | 0 (0%) | 0 (0%) | 0 (0%) |
| Warfarin | 4 (2.1%) | 0 (0%) | 0 (0%) |
| Clopidogrel | Ticagrelor or prasugrel | CI, P value | |
|---|---|---|---|
| STEMI: ST-elevation myocardial infarction; CI: confidence interval. | |||
| Race | |||
| White | 48.6% | 51.4% | 0.91 - 2.25, 0.115 |
| Non-White | 57.5% | 42.5% | |
| Sex | |||
| Male | 48.0% | 52.0% | 0.99 - 2.46, 0.053 |
| Female | 59.1% | 40.9% | |
| Insurance | |||
| Private insurance | 49.3% | 50.7% | 1.22 - 2.74, 0.003 |
| Non-private insurance | 64.0% | 36.0% | |